赛马鲁肽
杜拉鲁肽
医学
艾塞那肽
利拉鲁肽
安慰剂
内科学
2型糖尿病
不利影响
磷酸西他列汀
胃肠病学
糖尿病
血压
内分泌学
病理
替代医学
作者
P Andréadis,Thomas Karagiannis,Konstantinos Malandris,Ioannis Avgerinos,Aris Liakos,Apostolos Manolopoulos,Eleni Bekiari,David Matthews,Απόστολος Τσάπας
摘要
Semaglutide is a potent once-weekly GLP-1 RA, significantly reducing HbA1c, body weight and systolic blood pressure. However, it is associated with increased incidence of gastrointestinal adverse events. Results for pancreatitis and retinopathy require further assessment in post-approval pharmacovigilance studies.
科研通智能强力驱动
Strongly Powered by AbleSci AI